HUE036011T2 - Készítmény, mely tartalmaz egy gemcitabin-pro-gyógyszert - Google Patents

Készítmény, mely tartalmaz egy gemcitabin-pro-gyógyszert

Info

Publication number
HUE036011T2
HUE036011T2 HUE15733498A HUE15733498A HUE036011T2 HU E036011 T2 HUE036011 T2 HU E036011T2 HU E15733498 A HUE15733498 A HU E15733498A HU E15733498 A HUE15733498 A HU E15733498A HU E036011 T2 HUE036011 T2 HU E036011T2
Authority
HU
Hungary
Prior art keywords
gemcitabine
preparation containing
pro drug
pro
drug
Prior art date
Application number
HUE15733498A
Other languages
English (en)
Hungarian (hu)
Inventor
Hugh Griffith
Gordon Kennovin
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1411253.6A external-priority patent/GB201411253D0/en
Priority claimed from GBGB1417646.5A external-priority patent/GB201417646D0/en
Application filed by NuCana plc filed Critical NuCana plc
Publication of HUE036011T2 publication Critical patent/HUE036011T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HUE15733498A 2014-06-25 2015-06-25 Készítmény, mely tartalmaz egy gemcitabin-pro-gyógyszert HUE036011T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1411253.6A GB201411253D0 (en) 2014-06-25 2014-06-25 Prodrug
IN2050MU2014 2014-06-25
GBGB1417646.5A GB201417646D0 (en) 2014-10-06 2014-10-06 Formulations of phosphate derivatives

Publications (1)

Publication Number Publication Date
HUE036011T2 true HUE036011T2 (hu) 2018-06-28

Family

ID=53499028

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15733498A HUE036011T2 (hu) 2014-06-25 2015-06-25 Készítmény, mely tartalmaz egy gemcitabin-pro-gyógyszert

Country Status (30)

Country Link
US (4) US10117888B2 (cg-RX-API-DMAC7.html)
EP (2) EP3119794B1 (cg-RX-API-DMAC7.html)
JP (3) JP6855248B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220104270A (cg-RX-API-DMAC7.html)
CN (2) CN110882268A (cg-RX-API-DMAC7.html)
AU (2) AU2015278900B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016025787B1 (cg-RX-API-DMAC7.html)
CA (1) CA2944966C (cg-RX-API-DMAC7.html)
CL (1) CL2016003261A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119772T1 (cg-RX-API-DMAC7.html)
DK (1) DK3119794T3 (cg-RX-API-DMAC7.html)
EA (1) EA033046B1 (cg-RX-API-DMAC7.html)
ES (1) ES2655820T3 (cg-RX-API-DMAC7.html)
HK (1) HK1244437A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20180007T1 (cg-RX-API-DMAC7.html)
HU (1) HUE036011T2 (cg-RX-API-DMAC7.html)
IL (2) IL248345B (cg-RX-API-DMAC7.html)
LT (1) LT3119794T (cg-RX-API-DMAC7.html)
MX (2) MX373942B (cg-RX-API-DMAC7.html)
MY (1) MY186584A (cg-RX-API-DMAC7.html)
NO (1) NO3119794T3 (cg-RX-API-DMAC7.html)
PH (1) PH12016502552A1 (cg-RX-API-DMAC7.html)
PL (1) PL3119794T3 (cg-RX-API-DMAC7.html)
PT (1) PT3119794T (cg-RX-API-DMAC7.html)
RS (1) RS56752B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201608809RA (cg-RX-API-DMAC7.html)
SI (1) SI3119794T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800041T1 (cg-RX-API-DMAC7.html)
TW (2) TWI674097B (cg-RX-API-DMAC7.html)
WO (1) WO2015198059A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
ES2569185T3 (es) 2011-03-01 2016-05-09 Nucana Biomed Limited Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer
HUE033335T2 (en) 2012-11-16 2017-11-28 Univ College Cardiff Consultants Ltd Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate
RS56752B1 (sr) * 2014-06-25 2018-04-30 NuCana plc Formulacija koja sadrži gemcitabin-prolek
CA2945938C (en) 2014-06-25 2023-04-18 Nucana Biomed Limited Gemcitabine prodrugs
GB201417644D0 (en) * 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
PL3224268T3 (pl) 2014-11-28 2019-11-29 NuCana plc Nowe pochodne 3'-deoksyadenozyny amidofosforanów estrów aminokwasów 2' i/lub 5' jako związki przeciwnowotworowe
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN106539810B (zh) 2015-09-16 2021-03-09 济南高合医疗科技有限公司 一种富集了nuc-1031单一异构体的组合物及其制备方法和用途
CN108135920A (zh) 2015-10-05 2018-06-08 努卡那有限公司 组合疗法
HRP20211812T1 (hr) 2015-12-11 2022-03-04 NuCana plc Dijastereoselektivna sinteza derivata fosfata i prolijeka gemcitabina nuc-1031
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
KR102657458B1 (ko) 2016-11-02 2024-04-12 센트렉시온 테라퓨틱스 코포레이션 안정한 수성의 캡사이신 주사 가능한 제형 및 이의 의학적 용도
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
IL272036B2 (en) 2017-07-20 2025-01-01 Centrexion Therapeutics Corp Methods and compositions for treating pain using capsaicin
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
CN109956986B (zh) 2017-12-22 2021-04-27 浙江柏拉阿图医药科技有限公司 肝递送吉西他滨前体药物核苷环磷酸酯化合物及应用
WO2023076878A1 (en) * 2021-10-26 2023-05-04 Emphascience Inc. Ready-to-dilute formulation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE212661T1 (de) 1998-01-23 2002-02-15 Newbiotics Inc Durch enzymkatalyse erhaltene therapeutische substanzen.
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
ATE429438T1 (de) 1999-07-22 2009-05-15 Celmed Oncology Usa Inc Enzym katalisierte therapeutische aktivierung
CN1181829C (zh) * 2000-11-03 2004-12-29 中国人民解放军军事医学科学院附属医院 吉西他滨溶液制剂
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2006081364A2 (en) * 2005-01-27 2006-08-03 Erimos Pharmaceuticals Llc Formulations for injection of catecholic butanes, including ndga compounds, into animals
JP5528708B2 (ja) * 2006-02-09 2014-06-25 参天製薬株式会社 安定な製剤ならびにそれらを調製および使用する方法
EP1913962A1 (en) * 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
WO2011008985A2 (en) * 2009-07-15 2011-01-20 Georgia Tech Research Corporation Methods and compositions for improved delivery of therapeutic and diagnostic agents
KR20120086729A (ko) * 2009-11-20 2012-08-03 클라비스 파마 에이에스에이 젬시타빈 유도체의 비경구적 제제
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
KR101231925B1 (ko) * 2010-10-27 2013-02-08 씨제이제일제당 (주) 젬시타빈의 전구약물 및 이의 제조방법
ES2575676T3 (es) * 2012-01-20 2016-06-30 Aratana Therapeutics Nv Composición de colirio
CN104955458A (zh) * 2012-11-07 2015-09-30 Z·索 取代的吉西他滨芳基酰胺类似物和使用所述类似物的治疗方法
HUE033335T2 (en) 2012-11-16 2017-11-28 Univ College Cardiff Consultants Ltd Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate
CA2931458A1 (en) 2013-11-27 2015-06-04 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
CA2945938C (en) 2014-06-25 2023-04-18 Nucana Biomed Limited Gemcitabine prodrugs
RS56752B1 (sr) 2014-06-25 2018-04-30 NuCana plc Formulacija koja sadrži gemcitabin-prolek
ES2830784T3 (es) 2014-07-22 2021-06-04 NuCana plc Proceso para la preparación de gemcitabina-[fenil(benzoxi-L-alanil)]fosfato
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
DK3197456T3 (en) 2015-05-14 2018-06-06 NuCana plc CANCER TREATMENTS
CN108135920A (zh) 2015-10-05 2018-06-08 努卡那有限公司 组合疗法
HRP20211812T1 (hr) 2015-12-11 2022-03-04 NuCana plc Dijastereoselektivna sinteza derivata fosfata i prolijeka gemcitabina nuc-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
CA3008769A1 (en) 2015-12-23 2017-06-29 NuCana plc Combination therapy comprising nuc-1031 and cisplatin
EP3738595A1 (en) 2015-12-23 2020-11-18 Nucana PLC Combination therapy
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives

Also Published As

Publication number Publication date
CN106470672B (zh) 2019-11-05
TWI765176B (zh) 2022-05-21
MX388313B (es) 2025-03-19
WO2015198059A1 (en) 2015-12-30
LT3119794T (lt) 2018-02-12
SG11201608809RA (en) 2016-11-29
CA2944966C (en) 2022-10-25
CN106470672A (zh) 2017-03-01
PT3119794T (pt) 2018-01-15
CY1119772T1 (el) 2018-06-27
US10117888B2 (en) 2018-11-06
EP3119794A1 (en) 2017-01-25
CN110882268A (zh) 2020-03-17
HRP20180007T1 (hr) 2018-02-23
SI3119794T1 (en) 2018-02-28
US20190022118A1 (en) 2019-01-24
JP7329025B2 (ja) 2023-08-17
IL276199B (en) 2022-04-01
TW201945007A (zh) 2019-12-01
EA201692422A1 (ru) 2017-04-28
MY186584A (en) 2021-07-28
JP2017519022A (ja) 2017-07-13
HK1244437A1 (en) 2018-08-10
US11707477B2 (en) 2023-07-25
EP3269391A1 (en) 2018-01-17
CL2016003261A1 (es) 2017-10-06
JP2020079255A (ja) 2020-05-28
RS56752B1 (sr) 2018-04-30
TWI674097B (zh) 2019-10-11
BR112016025787B1 (pt) 2022-12-13
PL3119794T3 (pl) 2018-04-30
TW201613611A (en) 2016-04-16
JP6855248B2 (ja) 2021-04-07
AU2019204557B2 (en) 2020-08-27
CA2944966A1 (en) 2015-12-30
MX2016015629A (es) 2017-08-02
AU2015278900A1 (en) 2016-10-27
PH12016502552A1 (en) 2017-04-10
US20200397810A1 (en) 2020-12-24
US20220031727A1 (en) 2022-02-03
JP6970221B2 (ja) 2021-11-24
BR112016025787A2 (pt) 2017-08-15
NO3119794T3 (cg-RX-API-DMAC7.html) 2018-03-10
DK3119794T3 (en) 2018-01-22
ES2655820T3 (es) 2018-02-21
KR20170042501A (ko) 2017-04-19
JP2022031659A (ja) 2022-02-22
AU2019204557A1 (en) 2019-07-18
NZ725009A (en) 2021-02-26
KR20220104270A (ko) 2022-07-26
EA033046B1 (ru) 2019-08-30
IL248345A0 (en) 2016-11-30
MX2020004054A (es) 2021-11-30
US11040051B2 (en) 2021-06-22
US20170095498A1 (en) 2017-04-06
IL248345B (en) 2020-10-29
MX373942B (es) 2020-07-13
EP3119794B1 (en) 2017-10-11
AU2015278900B2 (en) 2019-04-04
KR102421929B1 (ko) 2022-07-15
SMT201800041T1 (it) 2018-03-08
US10786523B2 (en) 2020-09-29
IL276199A (en) 2020-09-30

Similar Documents

Publication Publication Date Title
HUE036011T2 (hu) Készítmény, mely tartalmaz egy gemcitabin-pro-gyógyszert
EP3344318A4 (en) Patient interfaces
DK3265421T3 (da) Doseringssystem
DK3140314T3 (da) Kaloriefrit sødestof
LT3188717T (lt) Vaisto forma, apimanti daleles
DK3259015T3 (da) Bioelektroniske lægemidler
DK3199161T3 (da) Farmaceutisk præparat
BR112017027227A2 (pt) Agente anti-câncer
EP3246047C0 (en) COMBINATION MEDICATION
HUE062326T2 (hu) Fokozott stabilitású gyógyászati készítmény
LT3256154T (lt) Farmacinė kompozicija, apimanti antikūną
KR20180084810A (ko) 정제 세트
HUE054584T2 (hu) Maropitant készítmény
EP3372264A4 (en) SYRINGE
EP3395344A4 (en) MEDICINE
DK3288967T3 (da) Farmaceutisk forbindelse
HUE050881T2 (hu) Gyógyszerkészítmény
EP3356047C0 (en) CALIBRATOR TOOTH
DK3288966T3 (da) Farmaceutisk forbindelse
DK3229868T3 (da) Lægemiddeladministrationsanordning, der omfatter en prisme
EP3355961C0 (de) Füllhilfe
UA30168S (uk) Сумка медична індивідуальна
UA31303S (uk) Логотип
UA31282S (uk) Логотип
UA30919S (uk) Логотип